Immutep Ltd (AU:IMM) has released an update.
Immutep Ltd has announced the receipt of positive feedback from the Spanish Agency for Medicines and Health Products for its Phase III TACTI-004 trial of eftilagimod alpha in treating metastatic non-small cell lung cancer. The trial will explore efti in combination with anti-PD-1 therapy, both with and without chemotherapy. Efti, a first-in-class antigen presenting cell activator, has already shown promise in earlier trials and has received Fast Track designation from the FDA for use in treating two types of cancer.
For further insights into AU:IMM stock, check out TipRanks’ Stock Analysis page.
